Chiesi Group Receives FDA Approval for Ferriprox (deferiprone) Twice-a-Day Tablets

BOSTON, May 21, 2020 (GLOBE NEWSWIRE) — Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today announced that the U.S. Food and Drug Administration (FDA)…Original Article